A genetic diagnosis for inherited muscle disease can end years of uncertainty, but standard short-read tests do not always find the cause. A Garvan Institute-led study published in Nature Communications reports that long-read nanopore sequencing identified a genetic cause in more than a third of previously unsolved cases in a small Australian cohort. The work points to a clinical pathway that NSW Health Pathology expects to roll out in about two years.
What the cohort measured
The study enrolled 53 Australians with suspected inherited muscle disease. Thirty-one had already been through genetic testing without an answer. On average, they had spent about 14 years without a molecular diagnosis. The research team used long-read nanopore sequencing, which reads much longer stretches of DNA than the short-read platforms used in many first-line tests. That matters for inherited muscle disease because some pathogenic variants are structural: large deletions or duplications, repeat expansions, insertions, or rearrangements that can be invisible or ambiguous on short reads.
The headline result is diagnostic yield, not a new treatment. In the previously unsolved group, the long-read test returned a cause for more than one-third. For families, that can mean a named condition rather than a broad label such as limb-girdle weakness or suspected myopathy. It can also clarify inheritance risk, guide cardiac and respiratory surveillance, and inform reproductive planning.
Why long reads can find what short reads miss
Short-read sequencing works by breaking DNA into small fragments and mapping them back to a reference. It is excellent at finding small spelling changes. It struggles when a variant involves a big chunk of DNA, sits in a repetitive region, or appears as a complex rearrangement. Long-read nanopore sequencing reads through those regions. The trade-off is that long-read data are heavier to process, and variant interpretation still needs clinical geneticists, pathologists, and genetic counsellors.
The Garvan cohort was selected because earlier testing had failed. That makes the yield notable, but it also means the result cannot be generalised to every person with a muscle disease. A clinic seeing unselected patients may find a different diagnostic rate. The study is also small at 53 people, and it does not show whether an earlier diagnosis changes muscle function, survival, or quality of life over time. Those questions need larger, longer studies.
The Australian lab question
For a CSIRO or campus lab, replicating the science is not the main hurdle. Nanopore sequencers are commercially available, and the wet-lab steps, from DNA extraction to library preparation, are established. The harder part is a clinical-grade pipeline: sample tracking, quality thresholds, bioinformatics for structural variant calling, accredited validation, and a multidisciplinary team to classify variants. NSW Health Pathology is positioned to take that translation step, with rollout flagged at about two years. Until then, access is likely to remain concentrated in research or specialist centres.
Cost and turnaround will decide whether long-read testing becomes a first-line test, a second-line test after short-read panels, or a targeted test for selected cases. Remote and rural patients also need a path to sample collection and genetic counselling if the benefit is not to sit only in metropolitan clinics.
NDIS and trial access stakes
A molecular diagnosis can matter beyond the clinic. It can strengthen evidence for NDIS planning, even though a genetic result alone does not determine funding. It can also open or close clinical trial eligibility, because many trials recruit by confirmed genetic subtype rather than by symptoms. For families who have spent years without an answer, that change in administrative and research access is part of the value.
The paper's contribution is a proof of diagnostic yield in a difficult group. It does not claim a cure, and it does not replace clinical assessment. The next useful studies will test the same approach in larger, more diverse Australian cohorts, compare cost and turnaround against current pathways, and track whether a diagnosis changes care. For now, the result gives unresolved families and their clinicians a concrete reason to ask whether long-read testing is available, and whether they can join the rollout when it reaches NSW Health Pathology.